Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | HPGD | P15428 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | PKM | P14618 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.53 |
| ▸ | GLA | P06280 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | CASP1 | P29466 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | CASP7 | P55210 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762972 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HPGDMAPTPKMKDM4E | |
| SCHEMBL929564 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HPGDMAPTPKMKDM4E | |
| SCHEMBL2762948 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HPGDMAPTPKMKDM4E | |
| SCHEMBL2763137 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HPGDMAPTPKMKDM4E | |
| SCHEMBL930783 | 0.76 | KDM4E (0.49) | ALDH1A1HPGDMAPTPKMKDM4E | |
| SCHEMBL928413 | 0.74 | ADORA2A (0.58) | MAPTHSD17B10ADORA2AADORA1ADORA2B | |
| SCHEMBL929260 | 0.72 | ADORA2A (0.60) | ADORA2AADORA1ADORA2B | |
| SCHEMBL21176819 | 0.69 | GRM4 (0.51) | ALDH1A1MAPTKDM4EADORA2AADORA1 | |
| SCHEMBL10692686 | 0.69 | POLB (0.49) | ALDH1A1HPGDMAPTKDM4EGAA | |
| SCHEMBL20658616 | 0.69 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPTPKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1720553-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R&D) LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005079801-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R & D) LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | ALDH1A1 562/4885HPGD 982/4885MAPT 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.